Pharmaceutical News

RSS

Lack of patient understanding of the true cost of medication non-adherence

A new report released today, Friday 16th October, by Omnicell, throws the spotlight on the ‘missing millions’ in the NHS and the staggering cost to the nation of medication non-adherence.

16 Oct 2015

New manganese-based catalyst may accelerate drug discovery, development

Chemists have long believed that inserting nitrogen -- a beneficial ingredient for making many pharmaceuticals and other biologically active molecules -- into a carbon-hydrogen bond requires a trade-off between catalyst reactivity and selectivity.

15 Oct 2015

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros Corporation today announced that it has launched OMIDRIAssure, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities.

15 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

BREVENA Laboratories receives National Eczema Association's Seal of Acceptance award for Restorative Skin Balm

BREVENA Laboratories, LLC, a luxury skincare cosmetics company that combines beauty and advanced medical technology, announces that the National Eczema Association has awarded the Seal of Acceptance to the brand's Restorative Skin Balm.

15 Oct 2015

Merck unveils new global brand as a science and technology company

Merck, a leading science and technology company, today announced the relaunch of its brand identity. The fundamental revision of the visual appearance as well as the introduction of a new logo reflect the transformation into a global science and technology company. At the same time, the brand architecture at business level has been simplified. Outside the United States and Canada, the company will operate uniformly as Merck.

15 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

Antipsychotic drugs more frequently used in Alzheimer's disease patients, new study finds

Antipsychotic drugs are initiated in patients with Alzheimer's disease (AD) more frequently than in the general population - already 2-3 years before the Alzheimer's diagnosis, according to a new study from the University of Eastern Finland.

14 Oct 2015

Insulin dose not independent risk factor for cardiovascular death

A NIH-sponsored double-blinded, randomized clinical trial entitled Action to Control Cardiovascular Risk in Diabetes (ACCORD study) came to a halt seven years ago after patients receiving more intensive diabetes therapy were found to have a higher mortality rate, compared to the standard therapy.

14 Oct 2015

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National Institutes of Health scientists and colleagues.

13 Oct 2015

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).

13 Oct 2015

Get your flu shot before fall festivities, says Loyola infectious disease specialist

While planning your family's fall festivities this month, add the flu shot to the list. Then follow through with a visit to your doctor to make sure everyone is protected for the flu season. October is the recommended month to receive the vaccine for your best shot at preventing the flu.

13 Oct 2015

Tamoxifen drug clears MRSA, reduces mortality

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments. Tamoxifen treatment in mice also enhances clearance of the antibiotic-resistant bacterial pathogen MRSA and reduces mortality.

13 Oct 2015

Men on effective HIV therapy less likely to get HBV infection, shows research

Previous studies of individuals with HIV have suggested that HIV drug regimens that included drugs active against hepatitis B virus (HBV) can decrease the risk of infection with the liver-damaging HBV.

13 Oct 2015

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

The Pharmacy Compounding Accreditation Board (PCAB) today reaffirmed the accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA.

13 Oct 2015

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease.

12 Oct 2015

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix Inc. today announced that U.S. Food and Drug Administration has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually.

12 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it.

12 Oct 2015

High dose flu vaccines significantly reduce hospitalization risk during influenza season

In the largest nursing home study to date on the effect of high dose flu vaccine, researchers found that shots with four times the strength of standard flu shots significantly reduced the risk of being hospitalized during the influenza season. There was a 1.2 percent difference (19.7 percent versus 20.9 percent) in admission for the group that received the high dose vaccine compared to the one that received the standard dose vaccine.

12 Oct 2015

Pharmaceutical News

Lack of patient understanding of the true cost of medication non-adherence

New manganese-based catalyst may accelerate drug discovery, development

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BREVENA Laboratories receives National Eczema Association's Seal of Acceptance award for Restorative Skin Balm

Merck unveils new global brand as a science and technology company

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Antipsychotic drugs more frequently used in Alzheimer's disease patients, new study finds

Insulin dose not independent risk factor for cardiovascular death

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

XTL signs agreement with Yeda to amend development milestones for lupus treatment

Get your flu shot before fall festivities, says Loyola infectious disease specialist

Tamoxifen drug clears MRSA, reduces mortality

Men on effective HIV therapy less likely to get HBV infection, shows research

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Lithium can be safe, effective for children suffering from bipolar disorder

High dose flu vaccines significantly reduce hospitalization risk during influenza season

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News